FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62403
News■ Unclear/unknown
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 16:22 UTC
LAST UPDATE2026-10-02 16:22 UTC
STATEsuperseded
01 THE MACHINE READ
WHY IT MATTERS.
Prison healthcare takeover ruling is a legal/administrative matter with no broad market transmission.
Legal ruling; negligible market impact
CATALYST TO WATCH
Implementation of state takeover
MAIN RISK
No investable relevance
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
←CORRELATIONshares Healthcare
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
←CORRELATIONshares Healthcare
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage2026-10-02 12:15 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.